Pulmonary arterial hypertension: changing approaches to management
Sidorenko, B.A.; Preobrazhenskiĭ, D.V.; Batyraliev, T.A.; Belenkov, I.N.
Kardiologiia 51(1): 100-108
2011
ISSN/ISBN: 0022-9040 PMID: 21626809 Document Number: 648808
The review is devoted to different aspects of pulmonary arterial hypertension (PAH); new classification of PAH is published in 2010. There are idiopathic PAH and PAH associated with other diseases. Current guidelines recommend to treat PAH only after the verification of diagnosis with right heart catheterization and acute tests with vasodilators. Patients-reactors should be treated with calcium antagonists. The following drugs related to one of three categories should be used in PAH: (1) prostanoids (epoprostenol, iloprost et al.); (2) blockers of endothelin receptors (bosentan, ambrisentan, sitaxsentan); (3) phosphodiesterase 5 type inhibitors (sildenafil, tadalafil et al.) In majority of cases the combined treatment is used, usually the combination of bosentan and sildenafil is used.